^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

RAD51AP1 as an Immune-Related Prognostic Biomarker and Therapeutic Response Predictor in Hepatocellular Carcinoma

Published date:
09/26/2023
Excerpt:
...whereas Bexarotene, Doxorubicin, Gemcitabine and Tipifarnib had lower IC50s, which suggested that the HCC patients with high-RAD51AP1 expression may be more susceptible to the treatment Bexarotene, Doxorubicin, Gemcitabine and Tipifarnib (all P < 0.05, Figure 11).
DOI:
https://doi.org/10.2147/IJGM.S431206